LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences:
- The Stifel 2018 Healthcare Conference on November 14, 2018, at 2:00 p.m. ET in New York, NY;
- The Jefferies 2018 London Healthcare Conference on November 15, 2018, at 11:20 a.m. GMT in London; and
- The Global Mizuho Investor Conference on December 4, 2018 in New York.
A live webcast of the Stifel and Jefferies presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the Stifel and Jefferies conference webcasts will be available on Concert’s website for two weeks following the presentations.
About Concert
Concert
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to treat serious diseases and address unmet patient
needs. The Company’s approach starts with previously studied compounds,
including approved drugs, in which deuterium substitution has the
potential to enhance clinical safety, tolerability or efficacy. Concert
has a broad
pipeline of innovative medicines targeting autoimmune and
inflammatory diseases and central nervous systems (CNS) disorders. For
more information please visit www.concertpharma.com
or follow us on Twitter at @ConcertPharma
or on LinkedIn.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
